Valuation: Vericel Corporation

Market Cap 2.32B 2.02B 1.89B 1.73B 3.26B 221B 3.3B 22.08B 8.67B 111B 8.72B 8.53B 368B P/E 2026 *
82.1x
P/E 2027 * 51.5x
Enterprise Value 2.32B 2.02B 1.89B 1.73B 3.26B 221B 3.3B 22.08B 8.67B 111B 8.72B 8.53B 368B EV / Sales 2026 *
6.91x
EV / Sales 2027 * 5.91x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day-1.34%
1 week-4.01%
Current month-2.63%
1 month-4.75%
3 months+21.57%
6 months+26.48%
Current year+24.27%
1 week 44.33
Extreme 44.3281
47.27
1 month 43.95
Extreme 43.95
49.32
Current year 28.95
Extreme 28.95
49.32
1 year 28.95
Extreme 28.95
49.32
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 2013-02-28
Director of Finance/CFO 51 2021-01-24
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 71 2005-09-27
Chairman 75 2012-10-04
Director/Board Member 57 2013-08-22
Date Insider Type Main position Quantity % Market Cap.
7/30/26 Fiscal year

Controller/Auditor

13,500 0.0264%
6/18/26 Fiscal year

General Counsel

45,000 0.0881%
2/24/26 Fiscal year

Chief Executive Officer

81,824 0.1618%
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%-4.01%+21.54%+39.84% 2.32B
+0.46%+11.03%+35.48%+0.74% 76.75B
-1.83%-10.32%+20.42%+182.81% 50.46B
+1.54%+2.37%-6.31%+23.71% 48.5B
+1.30%+3.35%-50.46%-50.08% 44.14B
-0.17%-1.41%+55.23%-23.29% 30.53B
-1.19%-6.86%+52.31%+86.04% 24.28B
-4.26%-1.16%+96.07%-50.22% 22.46B
+0.72%+1.39%-7.90%+177.29% 20.04B
+1.13%-5.79%+62.11%+120.47% 16.14B
Average -0.24%-0.68%+27.85%+50.73% 33.56B
Weighted average by Cap. +0.01%+1.03%+21.53%+41.89%

Financials

2026 *2027 *
Net sales 336M 292M 273M 250M 472M 32.03B 478M 3.2B 1.25B 16B 1.26B 1.23B 53.26B 393M 341M 319M 292M 551M 37.43B 559M 3.74B 1.47B 18.7B 1.48B 1.44B 62.24B
Net income 29.29M 25.42M 23.8M 21.77M 41.1M 2.79B 41.64M 278M 109M 1.39B 110M 108M 4.64B 47.29M 41.04M 38.43M 35.15M 66.36M 4.5B 67.23M 450M 176M 2.25B 178M 174M 7.49B
Net Debt - -
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
26-08-06 US$44.75 -1.34% 334,656
26-08-05 US$45.36 -2.11% 468,924
26-08-04 US$46.34 +0.63% 440,831
26-08-03 US$46.05 +0.20% 497,961
26-07-31 US$45.96 -3.47% 521,462
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
45.36USD
Average target price
60.57USD
Spread / Average Target
+33.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VCEL Stock